Authors: Pavia, CS Wormser, GP Nowakowski, J Cacciapuoti, A

Citation: Cs. Pavia et al., Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease, ANTIM AG CH, 45(3), 2001, pp. 936-937

Authors: Brieland, JK Jackson, C Menzel, F Loebenberg, D Cacciapuoti, A Halpern, J Hurst, S Muchamuel, T Debets, R Kastelein, R Churakova, T Abrams, J Hare, R O'Garra, A

Citation: Jk. Brieland et al., Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus, INFEC IMMUN, 69(3), 2001, pp. 1554-1560

Authors: Cacciapuoti, A Loebenberg, D Corcoran, E Menzel, F Moss, EL Norris, C Michalski, M Raynor, K Halpern, J Mendrick, C Arnold, B Antonacci, B Parmegiani, R Yarosh-Tomaine, T Miller, GH Hare, RS

Citation: A. Cacciapuoti et al., In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida, ANTIM AG CH, 44(8), 2000, pp. 2017-2022

Authors: Nomeir, AA Kumari, P Hilbert, MJ Gupta, S Loebenberg, D Cacciapuoti, A Hare, R Miller, GH Lin, CC Cayen, MN

Citation: Aa. Nomeir et al., Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys, ANTIM AG CH, 44(3), 2000, pp. 727-731